Delving into the Latest Updates on Guselkumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Guselkumab (Genetical Recombination), Guselkumab (genetical recombination) (JAN), Guselkumab (USAN)

+ [8]

Target

IL-23p19

Action

inhibitors

Mechanism

IL-23p19 inhibitors(Interleukin-23 subunit p19 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesCongenital Disorders+ [5]

Active Indication

Crohn's disease, active moderateCrohn's disease, active severeUlcerative colitis, active moderate+ [24]

Inactive Indication

Adenomatous Polyposis ColiCeliac DiseaseGeneralized Pustular Psoriasis+ [5]

Originator Organization

Janssen Global Services LLC

Active Organization

Janssen-Cilag International NVJanssen Scientific Affairs LLCJanssen Research & Development LLC

+ [11]

Inactive Organization-

License Organization

Janssen Pharmaceuticals, Inc.

Celsius Therapeutics, Inc.

MorphoSys AG

+ [3]

Drug Highest PhaseApproved

First Approval Date

United States (13 Jul 2017),

Plaque psoriasis

RegulationPriority Review (China), Breakthrough Therapy (China), Orphan Drug (Japan), Overseas New Drugs Urgently Needed in Clinical Settings (China)

Login to view timeline

Structure/Sequence

Sequence Code 9493545H

Source: *****

Sequence Code 9493571L

Source: *****

The goal of this observational registry study is to evaluate the real-world effectiveness and safety of IL-23 inhibitors in patients with psoriatic disease (psoriasis and/or psoriatic arthritis) treated in Costa Rica. The main questions it aims to answer are:
* Do IL-23 inhibitors (guselkumab or risankizumab) improve disease severity and quality of life in patients with psoriatic disease in routine clinical practice?
* What is the safety profile and treatment persistence of IL-23 inhibitors in this population?
* Patients receiving IL-23 inhibitors as part of their usual medical care will be followed longitudinally using standardized clinical measures (e.g., PASI, DLQI, DAPSA/BASDAI) and adverse-event reporting through a national registry.

Start Date01 May 2026

Sponsor / Collaborator-

CTIS2025-524573-16-00

/ Not yet recruitingPhase 4

OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE

Start Date30 Apr 2026

Sponsor / Collaborator

Getaid

NCT06916390

/ RecruitingPhase 4IIT

Guselkumab Intervention and Diet Evaluation for Pouchitis

Restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis (IPAA) is considered the procedure of choice in patients with ulcerative colitis (UC) refractory to medical therapy or with neoplasia. The most common complication after IPAA is the development of pouchitis. Pouchitis is clinically characterized by variable symptoms including increased stool frequency, altered consistency, bloody stools, abdominal cramping, urgency, and incontinence. Symptomatic pouchitis longer than four weeks is considered chronic pouchitis.
The conventional treatment for acute and chronic pouchitis is antibiotics, such as metronidazole and ciprofloxacin. The disease course of antibiotic responsive pouchitis may evolve into antibiotic dependent (requiring antibiotic maintenance therapy) pouchitis and then antibiotic refractory (no response to antibiotic treatment) pouchitis. Although many patients respond to antibiotic therapy, there is also evidence that suggest that aberrant regulation of the mucosal immune system might play a part in the pathogenesis of pouchitis arising from an abnormal mucosal immune response to a dysbiosis of the pouch microbiota. If individuals fail to respond to antibiotics, anti-tumor necrosis factor (anti-TNF) agents and vedolizumab have been proposed for the treatment of chronic pouchitis.
Guselkumab, an interleukin-23 (IL-23) p19 subunit antagonist monoclonal antibody, is proven to be efficacious in patients with moderately-to-severely active UC. Efficacy of guselkumab in treating UC has been shown in multiple large clinical trials. However, patients with pouchitis were never the targeted population and were even often excluded from the trials.
Pouchitis becomes a chronic problem with a huge impact in the quality of life of these patients. The incidence of pouchitis has been rising in the last decades. This increase might be explained by a change in dietary habits of this population.
This open label single center trial at UZ Leuven aims to evaluate the efficacy and safety of guselkumab in the treatment of chronic antibiotic refractory pouchitis during a 48-week treatment period, with or without a dietary intervention. Twenty subjects with a proctocolectomy and IPAA for UC who have developed chronic or relapsing pouchitis will be enrolled.

Start Date23 Apr 2026

Sponsor / Collaborator

Universitaire Ziekenhuizen KU Leuven

100 Clinical Results associated with Guselkumab

Login to view more data

100 Translational Medicine associated with Guselkumab

Login to view more data

100 Patents (Medical) associated with Guselkumab

Login to view more data

921

Literatures (Medical) associated with Guselkumab

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

On-label persistence in psoriasis after switching to guselkumab, tumor necrosis factor inhibitors, interleukin-17 inhibitors, or apremilast from other advanced therapies

Article

Author: Zhdanava, Maryia ; Fitzgerald, Timothy ; Feldman, Steven R. ; Boonmak, Porpong ; Schwartzbein, Samuel ; Libchaber, Béatrice ; Pilon, Dominic

OBJECTIVE:

To compare on-label persistence among adults with psoriasis who switched from other advanced therapies to guselkumab versus subcutaneous tumor necrosis factor inhibitors (SC TNFi), subcutaneous interleukin-17 inhibitors (SC IL-17i), or apremilast.

MATERIALS AND METHODS:

This retrospective cohort study used U.S. claims data from the IQVIA PharMetrics® Plus database (2016- 2023). Overlap propensity score weights were used to balance cohorts on baseline characteristics. On-label persistence was defined as the absence of drug discontinuation (event) and any dose change relative to the U.S. label (censoring). Survival analyses were used to assess on-label persistence from the start of the maintenance phase.

RESULTS:

At 12, 18, and 24 months after the start of the maintenance phase, respectively, on-label persistence was 190%, 180%, and 179% more likely on guselkumab versus SC TNFi; 78%, 87%, and 91% more likely on guselkumab versus SC IL-17i; and 187%, 199%, and 193% more likely on guselkumab versus apremilast (all p < 0.001).

CONCLUSIONS:

Patients experiencing suboptimal outcomes with other psoriasis-indicated advanced therapies achieved higher on-label persistence after switching to guselkumab, raising the potential for improved disease control relative to other treatment options.

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Real-world effectiveness and safety of guselkumab in adult patients with facial and/or genital psoriasis: a 52-week analysis from the Italian multicentric GULLIVER study

Article

Author: Pallotta, Sabatino ; Galluzzo, Marco ; Stingeni, Luca ; Megna, Matteo ; Argenziano, Giuseppe ; Corazza, Monica ; Lasagni, Claudia ; Piaserico, Stefano ; Fargnoli, Maria Concetta ; Costanzo, Antonio ; Bardazzi, Federico ; Offidani, Annamaria ; Bonifati, Claudio ; Richetta, Antonio Giovanni ; Potenza, Concetta ; Saibene, Federico ; Atzori, Laura ; Gramiccia, Talia ; Papini, Manuela ; Giofrè, Claudia ; Di Lernia, Vito Giuseppe ; Bongiorno, Maria Rita ; Dapavo, Paolo ; Prignano, Francesca ; Lembo, Serena ; Savoia, Paola ; Satolli, Francesca ; Burlando, Martina ; Guarneri, Claudio ; Zichichi, Leonardo ; Rongioletti, Franco ; Loconsole, Francesco ; Micali, Giuseppe ; Peris, Ketty ; Donini, Massimo ; Romanelli, Marco ; Stinco, Giuseppe ; Carrera, Carlo Giovanni

OBJECTIVES:

Facial and genital plaques are common manifestations of psoriasis, are challenging to treat, and significantly impact patients' quality of life (QoL).

METHODS:

GULLIVER is a prospective, non-interventional study conducted in 2020-2023 in Italy, aimed at examining the effectiveness, safety and QoL impact of guselkumab through 52 weeks of treatment in patients with facial and/or genital psoriasis. The primary endpoint was the percentage of patients achieving a static Physician Global Assessment (sPGA) score of ≤1 and a minimum 2-grade improvement in sPGA score at Week 52.

RESULTS:

Of 351 enrolled patients, 88.6% remained on guselkumab treatment at Week 52. The proportions of patients achieving the sPGA targets in the facial and genital groups, respectively, were 83.3% and 76.5% at week 12, increasing to 93.8% and 97.9% at Week 52. Mean Dermatology Life Quality Index score improved from 12.0 ± 7.5 at baseline to 1.1 ± 2.0 at Week 52 for patients with facial psoriasis (p-value <0.001) and from 12.0 ± 6.9 to 1.6 ± 3.5 for those with genital psoriasis (p-value <0.001). Guselkumab was well-tolerated and no new safety signals were identified.

CONCLUSIONS:

This Italian real-world study demonstrated the high effectiveness and a good safety profile of guselkumab in treating facial and genital psoriasis.

01 May 2026·INFLAMMATORY BOWEL DISEASES

Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.

Article

Author: Vetter, Marion L ; Van Rampelbergh, Rian ; Andrews, Jane M ; Corbett, Christopher ; Panaccione, Remo ; Panés, Julián ; Sands, Bruce E ; Terry, Nat A ; Afzali, Anita ; Salese, Leonardo ; van Duijnhoven, Wilbert ; Yee, Jacqueline ; Hisamatsu, Tadakazu ; Reinisch, Walter ; Danese, Silvio ; D'Haens, Geert R ; Rubin, David T

BACKGROUND:

The randomized, phase 2 GALAXI 1 study evaluated efficacy and safety of guselkumab, a dual-acting IL-23p19 subunit inhibitor, in participants with moderately to severely active Crohn's disease. Efficacy and safety through 5 years are reported.

METHODS:

After completing the 48-week, treat-through GALAXI 1 main study, participants could enter the long-term extension (LTE) and continue the subcutaneous maintenance regimen assigned at randomization. Efficacy for the combined guselkumab dose groups was analyzed by (1) as-observed analysis of LTE participants, (2) nonresponder imputation (NRI) analysis of LTE participants, and (3) NRI analysis of primary efficacy analysis set (all [week 0] randomized participants). The study was not designed for statistical comparisons between groups.

RESULTS:

Of 185 guselkumab-randomized participants in the primary efficacy analysis set, 151 participated in the LTE. Among those continuing treatment, with available data (as observed), 97.7% (n = 85 of 87) achieved clinical remission, 71.3% (n = 62 of 87) achieved endoscopic response, and 51.7% (n = 45 of 87) achieved endoscopic remission at week 240. Results from NRI analyses also showed durability of efficacy (eg, week-240 clinical remission: 59.2% [n = 84 of 142], LTE analysis set; 46.0% [n = 81 of 176], primary efficacy analysis set). High rates of clinical and endoscopic remission at week 240 were maintained in biologic-naive participants (97.8% [n = 45 of 46] and 54.3% [n = 25 of 46], respectively [as-observed]) and participants with an inadequate response or intolerance to biologic therapy (97.1% [n = 34 of 35] and 54.3% [n = 19 of 35], respectively [as-observed]). Event rates of serious adverse events, discontinuations due to adverse events, and serious infections were low in guselkumab-treated participants.

CONCLUSIONS:

Long-term guselkumab treatment showed sustained clinical and endoscopic efficacy through week 240. The long-term safety data were consistent with those previously presented in approved indications.

CLINICAL TRIAL REGISTRATION:

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (GALAXI), NCT03466411, https://clinicaltrials.gov/study/NCT03466411.

322

News (Medical) associated with Guselkumab

06 May 2026

·www.biopharmadive.com

Avalo shares spike on skin drug data; BioNTech to cut staff

Today, a brief rundown of news involving Avalo Therapeutics and BioNTech, as well as updates from Madrigal Pharmaceuticals and Johnson & Johnson and that you may have missed.Avalo Therapeutics shares spiked 45% on study results showing its experimental drug might be competitive with a fast-selling treatment for the chronic inflammatory skin condition hidradenitis suppurativa. According to Avalo, low and high doses of its therapy abdakibart met the primary objective of a Phase 2 study, triggering response rates of 42.2% and 42.9%, respectively, after 16 weeks about 17 percentage points higher than what was observed in placebo recipients. The positive findings follow clinical setbacks in hidradentitis suppurativa for Moonlake Immunotherapeutics and Insmed, both of which reported higher-than-expected placebo responses. Avalo saw a similar phenomenon, but still achieved results in line with Bimzelx, UCBs marketed treatment, wrote Stifel analyst Alex Thompson. Avalo quickly cashed in on the share surge by raising $375 million and disclosing plans to move abdakibart into late-stage testing.BioNTech is streamlining its manufacturing network, announcing in its latest earnings report plans to exit three sites in Germany and Singapore as well as all plants previously owned by CureVac, a company it acquired last year. BioNTech said the moves will affect 1,860 positions and are part of a broader cost-cutting strategy that should help it save upwards of 500 million euros, annually, starting in 2029. The savings will help BioNTech advance its cancer drug work now the companys main focus towards commercialization.Madrigal Pharmaceuticals added another prospect to its portfolio of treatments for the liver condition metabolic dysfunction-associated steatohepatitis, agreeing on Tuesday to license an experimental RNA-based medicine from Arrowhead Pharmaceuticals. Madigral is paying Arrowhead $25 million upfront, and could add another $975 million in milestones should the therapy hit a variety of developmental, regulatory and sales targets. Known as ARO-PNPLA3, the drug was once part of a collaboration with Johnson & Johnson before the big drugmaker handed back rights in 2023. Its now being positioned as a therapy for people with a particular genetic mutation thats highly prevalent among Hispanic patients with MASH.An experimental, double-barreled antibody from J&J missed its main objective in a pair of studies in inflammatory bowel disease, but will still head to late-stage testing. J&Js drug JNJ-4804 simultaneously targets IL-23 and TNF-, two known disease drivers and the targets of its medications Tremfya and Simponi. The drug was associated with higher remission rates than Simponi or Tremfya in the two studies, though the difference wasnt statistically significant. Still, J&J pointed to particularly promising outcomes in people who havent responded to one or two therapies, and is launching Phase 3 trials in people with ulcerative colitis and Crohns disease. Its not alone; others are pursuing similar two-pronged approaches. '

Phase 2Clinical ResultPhase 3Financial Statement

06 May 2026

·www.biospace.com

J&J pushes dual-antibody IBD therapy into Phase 3 despite mid-stage fails

iStock, cagkansayin Johnson & Johnson plans to advance the co-antibody therapy, which combines its IL-23 blocker Tremfya and the TNF-alpha inhibitor Simponi, into late-stage testing for Crohn’s disease and ulcerative colitis. Johnson & Johnson’s investigational antibody combo failed to significantly improve remission and response in a pair of mid-stage trials of inflammatory bowel diseases, but that isn’t stopping the pharma from forging ahead to pivotal testing. The investigational co-antibody therapy, dubbed JNJ-4804, is a fixed-dose combination of the pharma’s anti-IL-23 therapy Tremfya and TNF-alpha blocker Simponi. Combining both molecules in one therapy “yields a synergistic therapeutic approach” for patients resistant to monotherapies, Esi Lamousé Smith, vice president of J&J’s Gastroenterology Disease Area, said in a Tuesday release . Data presented Tuesday at Digestive Disease Week 2026 in Chicago, however, haven’t borne that out. In the Phase 2b DUET-CD study , high-dose JNJ-4804 showed significantly higher clinical remission and endoscopic response rates versus monotherapy with Simponi, but not versus Tremfya. This study focused on patients with moderate to severe Crohn’s disease with poor responses or intolerance to at least one prior line of systemic therapy. The mid-stage DUET-UC study , which focused on ulcerative colitis, reached similar outcomes—JNJ-4804 elicited significantly greater clinical remission than Simponi but not Tremfya. Endoscopic improvement, which in this study was set as a secondary endpoint, was “numerically higher” in those treated with the combo therapy versus Tremfya or Simponi alone. In a news release shared alongside these abstracts, however, J&J homed in on patients “who are considered highly refractory”—those who have shown suboptimal response to at least two classes of systemic therapies. In these populations, according to the pharma, JNJ-4804 elicited “meaningful improvements across multiple clinical and endoscopic measures.” These signals warrant further development, according to J&J, which on Tuesday said it would launch the Phase 3 DUET ENCORE-CD study in Crohn’s disease and DUET ENCORE-UC study in ulcerative colitis. “Although the DUET studies missed the primary endpoint, we do believe the positive trends support the idea that combination approaches are needed to raise the efficacy bar in IBD,” William Blair analysts wrote to investors on Tuesday. “However, with the signal being driven by the most refractory patients, we believe it also highlights the importance of targeting the right subpopulation,” they added. J&J hasn’t yet specified its target population for the DUET ENCORE programs, nor has it said when the studies are set to start.

Phase 2Phase 3Clinical ResultPhase 1ADC

05 May 2026

·endpoints.news

J&J's IBD combo fails Phase 2 studies, but will move into pivotal testing

Johnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy’s failure in two mid-stage trials. The company said that JNJ-4804, a combination of the blockbuster drugs Tremfya and Simponi, missed its primary endpoints in studies for Crohn’s disease and ulcerative colitis . However, the drug worked well enough in “highly refractory” patients who had seen their diseases progress after using at least two other treatments. J&J will launch two Phase 3 studies , one in ulcerative colitis and another in Crohn’s. By combining Tremfya and Simponi into one treatment, JNJ-4804 targets both IL-23 and TNF-alpha, two pathways known to be implicated in several inflammatory diseases. Both are also large pharmaceutical markets: In addition to Tremfya, AbbVie’s Skyrizi targets IL-23, while the one-time ultra-mega-blockbuster Humira goes after TNF-alpha. The theory is that going after both pathways at the same time can lead to better outcomes for patients. While this did not appear to bear out in all patients, the improvement was larger in the highly refractory subgroup. The primary endpoint in each study was clinical remission, and the trial design measured whether a greater proportion of patients could reach remission compared to placebo, as well as Tremfya and Simponi alone. JNJ-4804 scored a significantly higher remission rate compared to Simponi, but missed the statistical bar when measured against Tremfya. JNJ-4804 had to reach significance against both therapies to meet the primary endpoint. Researchers presented detailed results at the annual Digestive Disease Week conference in Chicago.

Phase 2Phase 3Clinical ResultPhase 1Clinical Trial Failure

100 Deals associated with Guselkumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10438	Guselkumab	L04AC16	DB11834

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Crohn's disease, active moderate	China	Janssen-Cilag International NV	20 Feb 2025
Crohn's disease, active severe	China	Janssen-Cilag International NV	20 Feb 2025
Ulcerative colitis, active moderate	United States	Janssen Biotech, Inc.	11 Sep 2024
Ulcerative colitis, active severe	United States	Janssen Biotech, Inc.	11 Sep 2024
Pustulosis of Palms and Soles	Japan	Janssen Pharmaceutical KK	21 Nov 2018
Colitis, Ulcerative	South Korea	Janssen Korea Ltd.	12 Apr 2018
Crohn Disease	South Korea	Janssen Korea Ltd.	12 Apr 2018
Keratoderma, Palmoplantar	South Korea	Janssen Korea Ltd.	12 Apr 2018
Erythrodermic psoriasis	Japan	Janssen Pharmaceutical KK	23 Mar 2018
Psoriasis	Japan	Janssen Pharmaceutical KK	23 Mar 2018
Pustular psoriasis	Japan	Janssen Pharmaceutical KK	23 Mar 2018
Arthritis, Psoriatic	European Union	Janssen-Cilag International NV	10 Nov 2017
Arthritis, Psoriatic	Iceland	Janssen-Cilag International NV	10 Nov 2017
Arthritis, Psoriatic	Liechtenstein	Janssen-Cilag International NV	10 Nov 2017
Arthritis, Psoriatic	Norway	Janssen-Cilag International NV	10 Nov 2017
Plaque psoriasis	United States	Janssen Biotech, Inc.	13 Jul 2017

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Juvenile Idiopathic Arthritis	NDA/BLA	United States	Johnson & Johnson	02 Dec 2024
Pediatric Crohn's Disease	Phase 3	United States	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Japan	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Australia	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Austria	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Belgium	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Brazil	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Canada	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	France	Janssen Research & Development LLC	13 Mar 2024
Pediatric Crohn's Disease	Phase 3	Israel	Janssen Research & Development LLC	13 Mar 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03466411 (GALAXI 1, Pubmed \| Inflamm Bowel Dis)	Phase 2	Crohn Disease	185	Guselkumab	zjgulkgjok(zobpruhaqi) = piydtnizvb xpllrkmzwo (sncbyxvoev ) View more	Positive	01 May 2026
				Guselkumab (LTE participants)	zjgulkgjok(zobpruhaqi) = zbujsxabzy xpllrkmzwo (sncbyxvoev )
NCT06039189 (SPECTREM, CTgov)	Phase 3	Plaque psoriasis	338	Placebo+Guselkumab (Group 1: Placebo Followed by Guselkumab 100 mg)	njrbpgrysy = vnxreesppc cbgnavuzfm (hhlgwotqho, bpiabsigcs - dpbeftesiw) View more	-	01 May 2026
				Guselkumab (Group 2: Guselkumab 100 mg)	njrbpgrysy = qjsltgisdq cbgnavuzfm (hhlgwotqho, awfsppueln - lhyyvodbcg) View more
NCT05528510 (ASTRO, Pubmed \| Lancet Gastroenterol Hepatol)	Phase 3	Colitis, Ulcerative	418	Guselkumab 400/100 mg	dmtbnhwdqo(oljpgalkgg) = fghmbtbcjm lkzxntiwij (artfpibzqf ) View more	Positive	01 Apr 2026
				Guselkumab 400/200 mg	dmtbnhwdqo(fxcdebxfvd) = vvuyxzfyhl kbcuqcnxwu (wekdvkjtnb ) View more
AAD2026	Not Applicable	Psoriasis \| Rheumatoid Arthritis	32	TNF- inhibitors (Systemic treatment)	zxndqwrvrx(fryctclcqw) = exaeizrvyn qgcqsywlfs (znvcbhdrrs )	Positive	27 Mar 2026
				methotrexate (Systemic treatment)	dqakvejojp(odnmbdqtdg) = jiwpmffbms ebctayuhjh (nqmpjahbrf )
AAD2026	Not Applicable	Psoriasis	26	Adalimumab	tzstoeckne(gjggauwiww) = nhxqohlrdv ieonhrrwva (asxuxteeik ) View more	Positive	27 Mar 2026
				Infliximab	tzstoeckne(gjggauwiww) = iurmglupil ieonhrrwva (asxuxteeik ) View more
SPECTREM (AAD2026)	Phase 3	Plaque psoriasis	338	Guselkumab 100mg	pwsgwjioga(qjmkbqmanq) = ilorzshait xcszuzaqmg (dhwurdotgs ) View more	Positive	27 Mar 2026
				Placebo	pwsgwjioga(qjmkbqmanq) = wfceriyvap xcszuzaqmg (dhwurdotgs ) View more
VISIBLE (AAD2026)	Phase 3	Plaque psoriasis	103	Guselkumab 100mg	wtofpzysca(tgdkgiyltd) = oxqkaajoxl cspcrxetyn (kcprtehmkk ) View more	Positive	27 Mar 2026
				Placebo	rpekvimlzy(qwtubnyraz) = mhfsvsaeya abisksbrkg (llerebwguj ) View more
GUIDE (AAD2026)	Phase 3	Plaque psoriasis	227	Guselkumab re-treatment	xgkgaftoms(ntddohbbxa) = uliykawshk xbrsxaxzdm (bknsannaov ) View more	Positive	27 Mar 2026
APEX (AAD2026)	Phase 3	Arthritis, Psoriatic	1,120	Guselkumab Q4W	chyumqgyzw(lgycgnybsp) = vqadxepgxi oxqibvwwbw (tlbqrwgkoh ) View more	Positive	27 Mar 2026
				Guselkumab Q8W	chyumqgyzw(lgycgnybsp) = txkzdtephj oxqibvwwbw (tlbqrwgkoh ) View more
AAD2026	Not Applicable	Plaque psoriasis	738	Apremilast	njlszfsigk(pvholrthnj) = qyvdhgpzsg rvpxhztmsa (kgjxoqljit ) View more	Positive	27 Mar 2026
				Etanercept	hmxxrvcosf(ezfqiarxvu) = ajywgwxzjc cbwvagupoi (vrnrmwcftf ) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data